VNOV VitaNova Life Sciences Corp
Wholesale-Apparel, Piece Goods & Notions · OTC · SEC CIK 1699709 · Fiscal year ends 04/30
Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY22.0%
TTM net income YoY-113.3%
TTM EPS YoY—
Revenue 3-yr CAGR420.5%
Net income 3-yr CAGR—
Margins
Gross margin26.9%
Operating margin-2.7%
Net margin-3.5%
FCF margin—
EBITDA margin—
Returns
ROE-6.0%
ROA-5.1%
ROIC (approx.)-11.9%
Asset turnover1.45x
Leverage & solvency
Liabilities / assets13.9%
Debt / equity0.00x
Current ratio7.13x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-4.89x
Accruals ratio-30.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-04-30 | FY20252025-04-30 | FY20242024-04-30 | FY20232023-04-30 | FY20222022-04-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $3.03M | $2.66M | $570,694 | $38,000 | $120,000 |
| Cost of revenue | $2.11M | $1.09M | $192,983 | $0 | — |
| Gross profit | $910,589 | $1.58M | $377,711 | $38,000 | — |
| SG&A expense | $733,795 | $158,122 | $86,753 | $62,227 | $133,367 |
| Operating income | $3,601 | $1.21M | $205,629 | -$24,227 | -$13,367 |
| Interest expense | $0 | $4,506 | $0 | — | — |
| Pretax income | $6,581 | $1.20M | $205,734 | -$24,227 | $139,682 |
| Income tax | $43,885 | $353,558 | $64,869 | $0 | $0 |
| Net income | -$37,304 | $850,746 | $140,865 | -$24,227 | $139,682 |
| EPS (basic) | -0.00 | 0.10 | 0.01 | 0.00 | 0.02 |
| EPS (diluted) | — | 0.03 | 0.01 | 0.00 | 0.02 |
| Weighted avg. shares (diluted) | — | 25.01M | 10.64M | 5.87M | 5.87M |
| Balance sheet | |||||
| Cash & equivalents | $1.60M | $782,810 | $593,036 | $8,728 | $23,103 |
| Receivables | $726,743 | $1.27M | $0 | — | — |
| Inventory | $105,613 | $44,247 | $132,873 | $0 | — |
| Current assets | $2.43M | $2.26M | $1.19M | $8,728 | $23,103 |
| Total assets | $2.45M | $2.26M | $1.19M | $8,728 | $23,103 |
| Current liabilities | $395,781 | $347,567 | $136,920 | $67,943 | $58,091 |
| Total liabilities | $395,781 | $347,567 | $136,920 | $67,943 | $58,091 |
| Shareholders' equity | $2.05M | $1.91M | $1.06M | -$59,215 | -$34,988 |
| Shares outstanding | 8.34M | 8.34M | 25.01M | 5.87M | 5.87M |
| Cash flow statement | |||||
| Operating cash flow | $814,407 | $192,774 | -$375,880 | -$18,375 | $4,061 |
| Financing cash flow | $0 | -$3,000 | $960,188 | $4,000 | $19,042 |
| Stock-based compensation | $179,400 | $2,000 | $1,000 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.